氯氮平药代动力学与药物基因组学的跨祖源纵向分析及全基因组关联研究
BACKGROUND: The antipsychotic, clozapine, is the only licensed drug against the treatment-resistant symptoms that affect 20-30% of people with schizophrenia.…
要点
- 撒哈拉以南非洲裔氯氮平平均代谢速度高于欧洲裔,东亚和西南亚裔慢代谢者比例高于欧洲裔。
- GWAS鉴定出8个药物基因组位点,其中7个在非欧洲群体中效应显著。
核心结论
- 跨祖源纵向GWAS可发现氯氮平代谢的药物基因组标记,这些标记单独或作为多基因评分在不同祖源间具有一致效应。
- 氯氮平代谢的祖源差异可考虑用于优化不同人群的氯氮平处方方案。
研究设计与样本
- 研究采用跨祖源GWAS设计,分析英国Zaponex治疗获取系统氯氮平监测服务(CLOZUK研究)中所有有临床医生申请氯氮平药代动力学检测的个体数据。
- 利用基因组信息识别五种生物地理祖源:欧洲、撒哈拉以南非洲、北非、西南亚和东亚。
- 进行药代动力学建模、GWAS和多基因风险评分关联分析,采用纵向回归分析,三个主要结局变量为氯氮平和去甲氯氮平血浆浓度及氯氮平与去甲氯氮平比值。
主要发现
- 撒哈拉以南非洲裔个体的平均氯氮平代谢速度高于欧洲裔个体。
- 东亚或西南亚裔个体比欧洲裔个体更可能是氯氮平慢代谢者。
临床怎么用
- 临床可考虑祖源差异对氯氮平代谢的影响,优化不同人群的氯氮平处方方案。
- 药物基因组标记或多基因评分可能有助于预测氯氮平血浆浓度和代谢比,但解释方差有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The antipsychotic, clozapine, is the only licensed drug against the treatment-resistant symptoms that affect 20-30% of people with schizophrenia. Clozapine is markedly underprescribed, partly because of concerns about its narrow therapeutic range and adverse drug reaction profile. Both concerns are linked to drug metabolism, which varies across populations globally and is partly genetically determined. Our study aimed to use a cross-ancestry genome-wide association study (GWAS) design to investigate variations in clozapine metabolism within and between genetically inferred ancestral backgrounds, to discover genomic associations to clozapine plasma concentrations, and to assess the effects of pharmacogenomic predictors across different ancestries. METHODS: In this GWAS, we analysed data from the UK Zaponex Treatment Access System clozapine monitoring service as part of the CLOZUK study. We included all available individuals with clozapine pharmacokinetic assays requested by their clinicians. We excluded people younger than 18 years, or whose records contained clerical errors, or with blood drawn 6-24 h after dose, a clozapine or norclozapine concentration less than 50 ng/mL, a clozapine concentration of more than 2000 ng/mL, a clozapine-to-norclozapine ratio outside of the 0·5-3·0 interval, or a clozapine dose of more than 900 mg/day. Using genomic information, we identified five biogeographical ancestries: European, sub-Saharan African, north African, southwest Asian, and east Asian. We did pharmacokinetic modelling, a GWAS, and a polygenic risk score association analysis using longitudinal regression analysis with three primary outcome variables: two metabolite plasma concentrations (clozapine and norclozapine) and the clozapine-to-norclozapine ratio. FINDINGS: 19 096 pharmacokinetic assays were available for 4760 individuals in the CLOZUK study. After data quality control, 4495 individuals (3268 [72·7%] male and 1227 [27·3%] female; mean age 42·19 years [range 18-85]) linked to 16 068 assays were included in this study. We found a faster average clozapine metabolism in people of sub-Saharan African ancestry than in those of European ancestry. By contrast, individuals with east Asian or southwest Asian ancestry were more likely to be slow clozapine metabolisers than those with European ancestry. Eight pharmacogenomic loci were identified in the GWAS, seven with significant effects in non-European groups. Polygenic scores generated from these loci were associated with clozapine outcome variables in the whole sample and within individual ancestries; the maximum variance explained was 7·26% for the metabolic ratio. INTERPRETATION: Longitudinal cross-ancestry GWAS can discover pharmacogenomic markers of clozapine metabolism that, individually or as polygenic scores, have consistent effects across ancestries. Our findings suggest that ancestral differences in clozapine metabolism could be considered for optimising clozapine prescription protocols for diverse populations. FUNDING: UK Academy of Medical Sciences, UK Medical Research Council, and European Commission.
引用
- Pardiñas AF, Kappel DB, Roberts M, et al. Pharmacokinetics and pharmacogenomics of clozapine in an ancestrally diverse sample: a longitudinal analysis and genome-wide association study using UK clinical monitoring data. Lancet Psychiatry. 2023. PMID: 36804072. doi:10.1016/S2215-0366(23)00002-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。